Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy.

Authors
Tran, Anna T
Mandall, P
Swindell, Ric
Hoskin, P
Bottomley, D
Logue, John P
Wylie, James P
Affiliation
The Christie NHS Foundation Trust, Manchester, UK. Electronic address: anna.tran@christie.nhs.uk.
Issue Date
2013-07-09

Metadata
Show full item record
Abstract
Routine use of I-125 interstitial brachytherapy (BT) alone in intermediate risk (IR) prostate cancer is controversial. It is often combined with external beam radiotherapy (EBRT). The biochemical outcome of a large cohort of only IR disease treated with BT monotherapy is reported.
Citation
Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy. 2013: Radiother Oncol
Journal
Radiotherapy and Oncology
URI
http://hdl.handle.net/10541/297452
DOI
10.1016/j.radonc.2013.05.030
PubMed ID
23849172
Type
Article
Language
en
ISSN
1879-0887
Collections